Journal
CLINICAL CANCER RESEARCH
Volume 21, Issue 21, Pages 4786-4800Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-1190
Keywords
-
Categories
Funding
- Fonds de la Recherche Scientifique (FNRS)
- Breast Cancer Research Foundation (BCRP)
- MEDIC foundation
- Les Amis de l'Institut Bordet
Ask authors/readers for more resources
Recent technological advances have enabled the detection and detailed characterization of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) in blood samples from patients with cancer. Often referred to as a liquid biopsy, CTCs and ctDNA are expected to provide real-time monitoring of tumor evolution and therapeutic efficacy, with the potential for improved cancer diagnosis and treatment. In this review, we focus on these opportunities as well as the challenges that should be addressed so that these tools may eventually be implemented into routine clinical care. (C)2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available